Sanofi and Regeneron Pharmaceuticals Inc. are gearing up to submit their PD-1 inhibitor Libtayo (cemiplimab) in first-line locally advanced or metastatic non-small cell lung cancer (NSCLC), a new, larger indication that would take the drug into the more competitive immuno-oncology market.
The companies announced on 27 April that a Phase III trial in high PD-L1 expressers met the primary endpoint of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?